Pharvaris (PHVS) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Company background and innovation

• Founded in 2016 to develop oral therapies for hereditary angioedema (HAE), leveraging expertise from the inventor of icatibant.

• Developed two formulations of the same active ingredient: one for on-demand treatment and one for prevention of HAE attacks.

• Both phase III studies are ongoing or set to initiate by year-end for on-demand and prophylactic use.

Clinical development and safety

• Oral B2 receptor antagonist is the first of its kind for long-term prophylactic HAE treatment.

• Over 300 healthy volunteers and long-term HAE patient data show the drug is well tolerated with no significant drug-related adverse events.

• On-demand and prophylactic studies are global, targeting 120 and 80 patients respectively, with enrollment across the U.S., Europe, Asia-Pacific, and Latin America.

Market landscape and patient needs

• HAE market is valued at $2.5–$2.8 billion, expected to grow to $4–$5 billion in the next few years, with 80%+ of sales in the U.S.

• U.S. market adoption is faster due to higher drug value perception; Europe lags due to pricing and slower adoption.

• Patients desire both efficacy and convenience; current injectables offer efficacy, while orals offer convenience but less efficacy—new oral aims to combine both.